Valchlor (mechlorethamine gel) / Helsinn, Recordati, Juniper Bio - LARVOL DELTA

Utilization and cost trends of topical mechlorethamine for cutaneous T-cell lymphoma in the United States: A Medicare part d analysis (ASH 2025) - "Valchlor remains a valuable therapy for CTCL; however, its rising cost and variable prescribing patterns warrant closer scrutiny, suggesting opportunities to improve prescribing practices and reduce overall costs. These data provide a foundation for further evaluation of real-world usage and can inform future value-based care strategies in CTCL management."

Medicare • Reimbursement • US reimbursement • Cutaneous T-cell Lymphoma • Dermatology • Hematological Disorders • Hematological Malignancies • Lymphoma • T Cell Non-Hodgkin Lymphoma

Stratum corneum ceramide profile as biomarker in cutaneous T-cell lymphoma (ISDS 2025) - "Treatment with chlormethine gel resulted in a partial normalization of the ceramide profile. To conclude, MF lesions exhibit a distinct and altered ceramide profile compared to non-lesional and healthy skin, which can partially be restored with topical treatment, qualifying ceramide profiling with tape-stripping as biomarker for disease monitoring."

Biomarker • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • T Cell Non-Hodgkin Lymphoma

Predicting response to topical chlormethine treatment in early-stage Mycosis Fungoides: optical coherence tomography vs. histology (ISDS 2025) - "Patients applied chlormethine gel for 16 weeks...In conclusion, OCT reliably measures epidermal thickness and correlates with clinical and histological findings. Our results suggest that epidermal thickness correlates with clinical response to chlormethine, thereby supporting its role as a non-invasive tool for monitoring therapeutic response."

Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • T Cell Non-Hodgkin Lymphoma

Chlormethine gel effectiveness as second-line treatment in mycosis fungoides: a single-centre retrospective study. (PubMed, Discov Oncol) - "Chlormethine gel appeared to be efficacious and safe as a second-line treatment for MF, including in advanced stages. Despite limitations like small sample size and retrospective design, these findings highlight its potential in combination therapies and the importance of continued treatment for optimal outcomes. Future research should confirm these results in larger, prospective studies."

Journal • Retrospective data • Cutaneous T-cell Lymphoma • Dermatitis • Dermatology • Hematological Malignancies • Immunology • Lymphoma • Mycosis Fungoides • Oncology

An Unusual Presentation of Mycosis Fungoides with Elevated Serum Tryptase (ACAAI 2025) - "He was initiated on omalizumab for persistent urticaria with partial improvement...He started treatment with mechlorethamine, showing good response...Discussion Although MF has not been associated with elevated tryptase levels, this patient’s persistently elevated tryptase with a negative evaluation for systemic mastocytosis raises questions about a potential association. This case also highlights the importance of thorough evaluations in patients with benign appearing, but persistent and refractory rashes, as conditions like MF may be overlooked."

Cardiovascular • Cutaneous T-cell Lymphoma • Dermatitis • Dermatology • Immunology • Mycosis Fungoides • Oncology • Urticaria • KIT

Chlormethine Gel Response and Dermatitis-Associated Modulation of the Tumor Microenvironment in Early-Stage MF (EORTC-CLTG 2025) - No abstract available

Biomarker • Tumor microenvironment • Oncology

Real-world experience with Chlormethine gel for Mycosis Fungoides treatment: results from a UK centre (EORTC-CLTG 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Cutaneous T-cell Lymphoma • Mycosis Fungoides • Oncology

Chlormethine gel experience from Kuwait Cancer Control Center (KCCC) (EORTC-CLTG 2025) - No abstract available

Oncology

Lipidomic profiling in cutaneous T-cell lymphoma: Comparative analysis of ceramide composition and treatment effect (EADV 2025) - "To conclude, MF lesions exhibit a distinct and altered ceramide profile compared to non-lesional and healthy skin, which can partially be restored with topical treatment."

Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • T Cell Non-Hodgkin Lymphoma

Effective Use of Mogamulizumab in CD30+ Large Cell Transformed Mycosis Fungoides: A Case of Early Remission (EADV 2025) - "Materials & Methods/Case presentation: We report a case of a 66-year-old male with a 10-year history of MF (stage T2bN0M0B0 at diagnosis), managed with multiple lines of therapy including PUVA, UVB, bexarotene, topical nitrogen mustard (Mustargen), chlormethine gel (Ledaga), and methotrexate—all with partial or no sustained response. Although Brentuximab vedotin remains a first-line option for CD30+ LCT-MF, this case illustrates the potential of mogamulizumab to induce both hematologic and unexpectedly rapid cutaneous responses, even in transformed disease. To our knowledge, this is the first report demonstrating successful use of mogamulizumab in a patient with CD30+ LCT-MF with rapid response both in blood and skin. Mogamulizumab may represent a safe and effective alternative in select refractory cases."

Clinical • Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology • CCR4 • TNFRSF8

Comprehensive characterization of the stratum corneum ceramide profile in cutaneous T-cell lymphoma (ESDR 2025) - "Treatment with chlormethine gel resulted in a partial normalization of the ceramide profile. To conclude, MF lesions exhibit a distinct and altered ceramide profile compared to non-lesional and healthy skin, which can partially be restored with topical treatment."

Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • T Cell Non-Hodgkin Lymphoma

Clinical and cellular effects of chlormethine gel in patients with cutaneous T-cell lymphoma of the mycosis fungoides type as mono- and combination therapy (ADO 2025) - No abstract available

Clinical • Combination therapy • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • T Cell Non-Hodgkin Lymphoma

Update on the mechanism of action and possible uses of chlormethine gel (ADO 2025) - "Sponsored by Recordati Rare Diseases Germany"

Rare Diseases

Topical Chlormethine Gel in the Treatment of Lymphomatoid Papulosis: A Case Report and Literature Review. (PubMed, J Clin Med) - "Six months post-treatment, the patient remained in remission. This case underscores the effectiveness of CG in achieving sustained remission in acral LyP, suggesting its potential as a treatment option for this rare condition."

Journal • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • TNFRSF8

Skin-Directed Therapies in Mycosis Fungoides: An Update. (PubMed, Dermatol Ther (Heidelb)) - "This review provides an updated overview of SDTs in MF treatment, including topical agents such as corticosteroids, retinoids, mechlorethamine, carmustine, imiquimod, as well as photodynamic therapy (PDT); phototherapy modalities including narrowband UVB (nb-UVB) and psoralen-UVA (PUVA); local radiotherapy; total skin electron beam radiotherapy (TSEBT) and total skin helical tomotherapy (TSHT). We review the indications, mechanisms of action, efficacy data, and adverse effect profiles associated with both established and emerging SDTs. Additionally, we present ongoing clinical trials evaluating emerging SDTs in the treatment of MF."

Journal • Review • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • T Cell Non-Hodgkin Lymphoma

SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) (clinicaltrials.gov) - P=N/A | N=840 | Recruiting | Sponsor: Leiden University Medical Center | Not yet recruiting ➔ Recruiting

Biomarker • Enrollment open • HEOR • Real-world evidence • Atopic Dermatitis • Chronic Lymphocytic Leukemia • Chronic Rhinosinusitis With Nasal Polyps • Chronic Spontaneous Urticaria • Conjunctivitis • Cutaneous T-cell Lymphoma • Dermatitis • Dermatology • Hematological Malignancies • Hidradenitis Suppurativa • Immunology • Inflammation • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • Psoriasis • Urticaria

A practical and safer model of nitrogen mustard injury in cornea. (PubMed, PLoS One) - "This model will allow safe evaluation of SM-like corneal injuries within 24 hours, facilitating the identification of early/new molecules that might help to develop novel treatments."

Journal • Corneal Abrasion • Fibrosis • Immunology • Inflammation • NECTIN1

FIL_CLOR-CTCL: Long-term Assessment of Chlormethine Gel in Mycosis Fungoides (clinicaltrials.gov) - P=N/A | N=190 | Not yet recruiting | Sponsor: Fondazione Italiana Linfomi - ETS

New trial • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Coexistence of Mycosis Fungoides and Photosensitive or Autoimmune Diseases. The Therapeutic Challenge: A retrospective Case Series from a Tertiary Referral Center. (PubMed, Isr Med Assoc J) - "Effective management of MF and associated photosensitive or autoimmune co-morbidities underscore the need for individualized treatment strategies in patients with these unique dual diagnoses."

Journal • Retrospective data • Cardiovascular • CNS Disorders • Cutaneous T-cell Lymphoma • Dermatology • Genetic Disorders • Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Metabolic Disorders • Mycosis Fungoides • Myositis • Oncology • Sezary Syndrome

Clinical outcomes of chlormethine gel in mycosis fungoides affecting "sensitive" areas: A retrospective case series. (PubMed, J Dtsch Dermatol Ges) - No abstract available

Clinical data • Journal • Retrospective data • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology

SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) (clinicaltrials.gov) - P=N/A | N=840 | Not yet recruiting | Sponsor: Leiden University Medical Center

Biomarker • HEOR • New trial • Real-world evidence • Atopic Dermatitis • Chronic Lymphocytic Leukemia • Chronic Rhinosinusitis With Nasal Polyps • Chronic Spontaneous Urticaria • Conjunctivitis • Cutaneous T-cell Lymphoma • Dermatitis • Dermatology • Hematological Malignancies • Hidradenitis Suppurativa • Immunology • Inflammation • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • Psoriasis • Urticaria

MSD’s Welireg fails reimbursement review again, while Ledaga Gel and Omjjara secure insurance coverage (Korea Biomedical Review) - "MSD's rare disease drug Welireg (belzutifan) has failed to secure reimbursement in its second attempt....Welireg, Ledaga Gel (chlormethine), and Omjjara (momelotinib) were evaluated for new reimbursement. While Ledaga Gel and Omjjara successfully established reimbursement standards, Welireg failed to pass....Welireg is an oral HIF-2α inhibitor indicated for treating renal cell carcinoma, central nervous system hemangioblastoma, and pancreatic neuroendocrine tumors in adult patients with von Hippel-Lindau (VHL) disease who do not require immediate surgery....In October 2024, Synex received approval from the Ministry of Food and Drug Safety for Ledaga Gel as a topical treatment for adult patients with early-stage mycosis fungoides cutaneous T-cell lymphoma (MF-Type CTCL) who had previously undergone skin-directed therapy....GSK’s Omjjara...approved in September 2024 for treating intermediate- or high-risk myelofibrosis."

Reimbursement • Cutaneous T-cell Lymphoma • Hemangioblastoma • Myelofibrosis • Neuroendocrine Neoplasm • Pancreatic Cancer • Renal Cell Carcinoma • Von Hippel-Lindau Syndrome

Systemic Targeted Therapies in Patients with Relapsed/Refractory Advanced Stage Cutaneous T-cell Lymphoma: A Real-world Single-centre Case Series. (PubMed, Acta Derm Venereol) - "Early stages are often controlled with skin-directed therapy, such as topical corticosteroids, topical chlormethine gel, or UV therapy, whereas advanced stages often warrant a more aggressive approach with systemic antibody targeted therapy including mogamulizumab, brentuximab vedotin, or alemtuzumab. Median time to progression was 2.5, 4, and 11 months, respectively. In conclusion, this paper offers a unique perspective on the complexities of clinical practice when managing advanced-stage cutaneous T-cell lymphomas and demonstrates the effectiveness of the therapies described, with particular emphasis on the promising results observed with alemtuzumab administered in a low-dose protocol."

Journal • Real-world evidence • Retrospective data • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma

Topical mechlorethamine for cutaneous T-cell lymphoma: a historical perspective (EADO-WCM 2025) - "Advances in formulation and concentration have resulted in chlormethine 0, 016% gel, wich represents a viable treatment option within the therapeutic armamentarium for MF. This treatment has demonstrated significant efficacy in early-stage cases and shows promise for use in combination therapies for advanced stages of the disease."

Atopic Dermatitis • Contact Dermatitis • Cutaneous Lupus Erythematosus • Cutaneous T-cell Lymphoma • Dermatitis • Dermatology • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lupus • Lymphoma • Mycosis Fungoides • Oncology • T Cell Non-Hodgkin Lymphoma

Mycosis Fungoides Treatment with Chlormethine - Treatment Challenges and Clinical Outcome: Case Report (EADO-WCM 2025) - "Topical chlormethine (CL) gel is the first cytotoxic chemotherapy gel specifically designed for the treatment of MF...The addition of emollients and topical steroids also improves treatment maintenance. While continued therapy is essential, the majority of patients have good responses to CL gel."

Case report • Clinical • Clinical data • Contact Dermatitis • Cutaneous T-cell Lymphoma • Dermatitis • Dermatology • Hematological Malignancies • Immunology • Lymphoma • Mycosis Fungoides • Oncology • T Cell Non-Hodgkin Lymphoma